ReviewJournal of ovarian research2019
Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review.
Review in Journal of ovarian research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02326064 (Prospective Multicenter Study in Patients With a Tumor Benign Ovarian Presumed on the Use of Algorithms Such as Roma and RMI), which is not on this map. Cited by 301 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospective Multicenter Study in Patients With a Tumor Benign Ovarian Presumed on the Use of Algorithms Such as Roma and RMI (Risk of Malignancy Index) and Tumor Markers Such as CA125 (Cancer Antigen 125) and HE4 (Human Epididymal Protein 4)
Who cites it
301 citing papers in PubMed, 6 syntheses or guidelines pooled it, 583 citations in OpenAlex.
- AI-Derived Blood Biomarkers for Ovarian Cancer Diagnosis: Systematic Review and Meta-Analysis.Journal of medical Internet research · 2025Pooled it
- The Role of CA-125 in the Management of Ovarian Cancer: A Systematic Review.Cancer reports (Hoboken, N.J.) · 2025Pooled it
- Comparing the diagnostic efficacy of [Abdominal radiology (New York) · 2025Pooled it
- Utility of CA-125 for diagnosis and prognosis of breast cancer: a systematic review.Exploration of targeted anti-tumor therapy · 2025Pooled it
- p27Histology and histopathology · 2025Pooled it
- The association between endometriosis and risk of endometrial cancer and breast cancer: a meta-analysis.BMC women's health · 2022Pooled it
- A Novel Approach to Reducing Chemoresistance in Advanced Ovarian Cancer: The Effect of Itraconazole-A Single-Institution Randomized Placebo-Controlled Trial.Current oncology (Toronto, Ont.) · 2025Trial
- Platelet activation and eicosanoid signaling in ovarian cancer: implications for biomarker development.Molecular biology reports · 2026Review
- Rapid serum-based differentiation of ovarian tumors and assessment of post-treatment disease-free status using portable Raman spectroscopy and machine learning.Analytical and bioanalytical chemistry · 2026Article
- Assessment of the Targeted Therapeutic Potential of Naringenin-Benzyl Piperazine Derivatives on Hypoxia-Induced JAK/STAT Pathway in Breast and Ovarian Cancers.Archiv der Pharmazie · 2026Article
- Baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer: Results from a GINECO/GINEGEPS study of the randomized phase II CHIVA trial.Translational oncology · 2026Article
- Article
- Expanding High-Fidelity Multiplexing in Ultrasensitive Single-Molecule Protein Detection via Proximity Barcoding.Angewandte Chemie (International ed. in English) · 2026Article
- DNA Methylation and mRNA Expression of SEPT9 and AKR1B1 in Ovarian Cancer: Diagnostic and Prognostic Implications.International journal of molecular sciences · 2026Article
- Article
- Liquid Biopsy-Based Metabolomics in Epithelial Ovarian Cancer: Challenges, Methodological Advances and Translational Considerations.Diagnostics (Basel, Switzerland) · 2026Review
- Diagnostic Potential of Selected Matrilysins and Stromelysins in the Diagnosis of Gynecological Malignancies Based on ROC Curve Analysis.International journal of molecular sciences · 2026Article
- Evaluation of the TiaoShenZhiAi Regimen for Patients With Ovarian Cancer Experiencing a Psychoneurological Symptom Cluster: Protocol for a Multicenter, Double-Blind, Randomized Controlled Trial.JMIR research protocols · 2026Article
- Selenium-Based Nanoplatforms: An Emerging Theranostic Paradigm for Gynecological Cancers.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Predictive ability of novel glycovariant biomarkers of CA125 and CA15-3 up to three years prior to ovarian cancer diagnosis: a population-based case-control study.Journal of ovarian research · 2026Article
241 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer is the 5th leading cause of death for women with cancer worldwide. In more than 70% of cases, it is only diagnosed at an advanced stage. Our study aims to give an update on the biological markers for diagnosing ovarian cancer, specifically HE4, CA 125, RMI and ROMA algorithms.Serum CA125 assay has low sensitivity in the early stages and can be increased in certain conditions such as menstruation or endometriosis. The level of HE4 is overexpressed in ovarian tumors. Its specificity is 94% and its level is not affected by endometriosis cysts. The combined measures of CA125 and HE4 have proved to be highly efficient with an area under the curve (AUC) of up to 0.96. Furthermore, this combined measure of CA125 can correct the variations in HE4 which are due to smoking or contraception combining estrogen plus progestin. While the specificity of RMI sometimes reaches 92%, the rather low AUC of 0.86 does not make it the best diagnostic tool. The specificity of ROMA is lower than HE4 (84% compared to 94%).To date, the most efficient biological diagnostic tool to diagnose ovarian cancer is the combination of CA125 and HE4.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.